Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community

被引:13
作者
Genta, MS [1 ]
Kardes, H [1 ]
Gabay, C [1 ]
机构
[1] Univ Hosp Geneva, Dept Internal Med, Div Rheumatol, CH-1211 Geneva 14, Switzerland
关键词
rheumatoid arthritis; anti-TNF-alpha agents; community-based study;
D O I
10.1016/j.jbspin.2005.07.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. - TNF-alpha inhibitors have been effective in randomized controlled studies for the treatment of RA. The purpose of this study was to evaluate the clinical, laboratory, and radiological responses in a cohort of unselected patients with RA treated with TNF-a inhibitors in the community. Methods. - Using the Swiss Clinical Quality Management in Rheumatoid Arthritis, a centralized system of data gathering for RA patients, we obtained the following information regarding patients treated with a TNF-a inhibitor in the Geneva Canton before 02/2003: demographics; clinical data (disease activity, functional status, treatments received and type of TNF-a inhibitor used); laboratory and radiographic data. Results. - A total of 66 patients (mean age = 60.5 years) with long-standing disease (mean duration = 12.5 years) were analyzed. Sixteen patients (24%) discontinued anti-TNF-alpha, half within the first 6 months of the study. Mean DAS score decreased from 4.8 +/- 0.4 to 3.8 +/- 0.4 (P < 0.01); HAQ scores (mean = 1.35) remained unchanged; pain, evaluated on a 10-point scale, decreased from 5.0 at baseline to 3.3 (P < 0.001). CRP values decreased steadily from 17.9 at baseline to 5.6 at 20 months or later. The progression of radiographic damage decelerated in 30 patients, accelerated in 12, and remained unchanged in one. Conclusions. - The responses of this community-based group of patients with severe, long-standing RA to TNF-alpha inhibitors revealed a reassuring similarity to those of patients enrolled in controlled clinical trials. (c) 2005 Elsevier SAS. All rights reserved.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 23 条
[11]   Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial [J].
Maini, R ;
St Clair, EW ;
Breedveld, F ;
Furst, D ;
Kalden, J ;
Weisman, M ;
Smolen, J ;
Emery, P ;
Harriman, G ;
Feldmann, M ;
Lipsky, P .
LANCET, 1999, 354 (9194) :1932-1939
[12]   Anticytokine therapy - A new era in the treatment of rheumatoid arthritis? [J].
O'Dell, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (04) :310-312
[13]   Drug therapy - Therapeutic strategies for rheumatoid arthritis [J].
O'Dell, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2591-2602
[14]   Drug therapy - New drugs for rheumatoid arthritis [J].
Olsen, NJ ;
Stein, CM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2167-2179
[15]   MODIFIED DISEASE-ACTIVITY SCORES THAT INCLUDE 28-JOINT COUNTS - DEVELOPMENT AND VALIDATION IN A PROSPECTIVE LONGITUDINAL-STUDY OF PATIENTS WITH RHEUMATOID-ARTHRITIS [J].
PREVOO, MLL ;
VANTHOF, MA ;
KUPER, HH ;
VANLEEUWEN, MA ;
VANDEPUTTE, LBA ;
VANRIEL, PLCM .
ARTHRITIS AND RHEUMATISM, 1995, 38 (01) :44-48
[16]  
Rau R, 1998, J RHEUMATOL, V25, P2094
[17]   Standardising joint assessment in rheumatoid arthritis [J].
Scott, DL ;
Choy, EHS ;
Greeves, A ;
Isenberg, D ;
Kassinor, D ;
Rankin, E ;
Smith, EC .
CLINICAL RHEUMATOLOGY, 1996, 15 (06) :579-582
[18]   Anti-tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis:: No clear answer [J].
Symmons, DPM ;
Silman, AJ .
ARTHRITIS AND RHEUMATISM, 2004, 50 (06) :1703-1706
[19]   Clinical quality management in rheumatoid arthritis: putting theory into practice [J].
Uitz, E ;
Fransen, J ;
Langenegger, T ;
Stucki, G .
RHEUMATOLOGY, 2000, 39 (05) :542-549
[20]   A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [J].
Weinblatt, ME ;
Kremer, JM ;
Bankhurst, AD ;
Bulpitt, KJ ;
Fleischmann, RM ;
Fox, RI ;
Jackson, CG ;
Lange, M ;
Burge, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (04) :253-259